MAOA and cholangiocarcinoma: Previous studies reported that hypermethylation of the MAOA promoter contributes to its downregulation in cholangiocarcinomas and nasopharyngeal carcinoma, while treatment with the DNMT inhibitor, 5-Aza, restores its expression in both cancers [15,38].